Overview

First-in-human Evaluation of [18F]CETO

Status:
Completed
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
Purpose of this clinical phase 1 trial was to determine if para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used in diagnostics of adrenal tumors and if the biochemical/pharmacological states conditions in humans with various illnesses, compared to healthy humans, such as the radio tracer is suitable?
Phase:
Early Phase 1
Details
Lead Sponsor:
Uppsala University
Collaborators:
British Medical Research Council
Uppsala University Hospital